Male Infertility: XII. Pharmacological Treatment for Improving Semen Motility / 대한비뇨기과학회지

ABSTRACT

Some investigators suggest that the pancreatic proteinase kallikrein plays an important role in the regulation of spermatozoal motility. Particularly, oral kallikrein therapy exerted a favorable effect on Sperm motility in oligozoospermia and asthenozoospermia. We have carried out a similar clinical investigation of the efficacy of kallikrein, taken orally 60 kU per day for 3-9 months, on the quantitative and qualitative motility of spermatozoa in normogonadotropic infertile men. with 15 idiopathic oligozoospermia and 18 idiopathic asthenozoospermia. Number of spermatozoa increased more than double number of basic levels (over 40 x 10(6)/ml) in the 5 patients (33%) and pregnancy occurred in the 3 patients (20%) out of the 15 patients with idiopathic oligozoospermia (less than 20 x 10(6)/ml) after the kallikrein therapy. In these responded 5 patients, the sperm concentration changed from 13.6 x 10(6)/ml to 54.0 x 10(6)/ml, Motility and viability of spermatozoa improved more than 30% in the 5 patients (28%) and pregnancy occurred in the 2patients (11%) out of the 18 patients with idiopathic asthenozoospermia (less than 20% of sperm motility) after the therapy. In these. improved 5 patients, the sperm motility changed from 9.0% to 45.0%. No remarkable side effect was detected.